Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
NCT02923011
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years. The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Osteoid Osteoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 8 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Matthew Bucknor
- Last updated on ClinicalTrials.gov
- February 19, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Stanford Medical Center · Palo Alto, CA
- UCSF Imaging Center · San Francisco, CA
Minnesota · 1
- Mayo Clinic · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.